Literature DB >> 22234692

Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.

Srinivas Koduru1, Ellice Wong, Till Strowig, Ranjini Sundaram, Lin Zhang, Matthew P Strout, Richard A Flavell, David G Schatz, Kavita M Dhodapkar, Madhav V Dhodapkar.   

Abstract

Tumor microenvironment (TME) is commonly implicated in regulating the growth of tumors, but whether it can directly alter the genetics of tumors is not known. Genomic instability and dendritic cell (DC) infiltration are common features of several cancers, including multiple myeloma (MM). Mechanisms underlying genomic instability in MM are largely unknown. Here, we show that interaction between myeloma and DCs, but not monocytes, leads to rapid induction of the genomic mutator activation-induced cytidine deaminase (AID) and AID-dependent DNA double-strand breaks (DSBs) in myeloma cell lines as well as primary MM cells. Both myeloid as well as plasmacytoid DCs have the capacity to induce AID in tumor cells. The induction of AID and DSBs in tumor cells by DCs requires DC-tumor contact and is inhibited by blockade of receptor activator of NF-κB/receptor activator of NF-κB ligand (RANKL) interactions. AID-mediated genomic damage led to altered tumorigenicity and indolent behavior of tumor cells in vivo. These data show a novel pathway for the capacity of DCs in the TME to regulate genomic integrity. DC-mediated induction of AID and resultant genomic damage may therefore serve as a double-edged sword and be targeted by approaches such as RANKL inhibition already in the clinic.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234692      PMCID: PMC3311257          DOI: 10.1182/blood-2011-08-376236

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma.

Authors:  J W Said; M R Rettig; K Heppner; R A Vescio; G Schiller; H J Ma; D Belson; A Savage; I P Shintaku; H P Koeffler; H Asou; G Pinkus; J Pinkus; M Schrage; E Green; J R Berenson
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

2.  A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus.

Authors:  Polyxeni Gourzi; Tatyana Leonova; F Nina Papavasiliou
Journal:  Immunity       Date:  2006-06       Impact factor: 31.745

3.  Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.

Authors:  M Muramatsu; K Kinoshita; S Fagarasan; S Yamada; Y Shinkai; T Honjo
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

4.  Role of genomic instability and p53 in AID-induced c-myc-Igh translocations.

Authors:  Almudena R Ramiro; Mila Jankovic; Elsa Callen; Simone Difilippantonio; Hua-Tang Chen; Kevin M McBride; Thomas R Eisenreich; Junjie Chen; Ross A Dickins; Scott W Lowe; Andre Nussenzweig; Michel C Nussenzweig
Journal:  Nature       Date:  2006-01-08       Impact factor: 49.962

5.  Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.

Authors:  D Chauhan; A Bharti; N Raje; E Gustafson; G S Pinkus; J L Pinkus; G Teoh; T Hideshima; S P Treon; J D Fingeroth; K C Anderson
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

6.  The relative spatial distribution of CFU-S in the mouse spleen.

Authors:  R E Ploemacher; N H Brons
Journal:  Exp Hematol       Date:  1985-11       Impact factor: 3.084

7.  AID is required for c-myc/IgH chromosome translocations in vivo.

Authors:  Almudena R Ramiro; Mila Jankovic; Thomas Eisenreich; Simone Difilippantonio; Selina Chen-Kiang; Masamichi Muramatsu; Tasuku Honjo; André Nussenzweig; Michel C Nussenzweig
Journal:  Cell       Date:  2004-08-20       Impact factor: 41.582

8.  Expression of the AID protein in normal and neoplastic B cells.

Authors:  Laura Pasqualucci; Roberta Guglielmino; Jane Houldsworth; Jessica Mohr; Said Aoufouchi; Roberto Polakiewicz; R S K Chaganti; Riccardo Dalla-Favera
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

9.  In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas.

Authors:  D Bell; P Chomarat; D Broyles; G Netto; G M Harb; S Lebecque; J Valladeau; J Davoust; K A Palucka; J Banchereau
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

10.  Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Keren Osman; Matthew D Geller
Journal:  J Exp Med       Date:  2003-11-24       Impact factor: 14.307

View more
  23 in total

Review 1.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

2.  PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER.

Authors:  Robert Hromas; Elizabeth Williamson; Suk-Hee Lee; Jac Nickoloff
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

3.  Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.

Authors:  Shiny Nair; Andrew R Branagan; Jun Liu; Chandra Sekhar Boddupalli; Pramod K Mistry; Madhav V Dhodapkar
Journal:  N Engl J Med       Date:  2016-02-11       Impact factor: 91.245

Review 4.  Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

Authors:  Fotis Asimakopoulos; Chelsea Hope; Michael G Johnson; Adam Pagenkopf; Kimberly Gromek; Bradley Nagel
Journal:  J Leukoc Biol       Date:  2017-03-02       Impact factor: 4.962

Review 5.  Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.

Authors:  Michael Heider; Katharina Nickel; Marion Högner; Florian Bassermann
Journal:  Oncol Res Treat       Date:  2021-11-08       Impact factor: 2.825

Review 6.  Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.

Authors:  Daniela N Petrusca; Kelvin P Lee; Deborah L Galson
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 7.  Immune Modulation in Hematologic Malignancies.

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

8.  Transcription factor binding at Ig enhancers is linked to somatic hypermutation targeting.

Authors:  Ravi K Dinesh; Benjamin Barnhill; Anoj Ilanges; Lizhen Wu; Daniel A Michelson; Filip Senigl; Jukka Alinikula; Jeffrey Shabanowitz; Donald F Hunt; David G Schatz
Journal:  Eur J Immunol       Date:  2019-12-19       Impact factor: 5.532

Review 9.  Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective.

Authors:  Elisa Taiana; Maria Eugenia Gallo Cantafio; Vanessa Katia Favasuli; Cecilia Bandini; Giuseppe Viglietto; Roberto Piva; Antonino Neri; Nicola Amodio
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

Review 10.  Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.

Authors:  Cirino Botta; Francesco Mendicino; Enrica Antonia Martino; Ernesto Vigna; Domenica Ronchetti; Pierpaolo Correale; Fortunato Morabito; Antonino Neri; Massimo Gentile
Journal:  Cancers (Basel)       Date:  2021-06-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.